Opus Genetics Reports $8.1 Million Net Loss in Q2 2026, Increased Operating Expenses

Opus Genetics, Inc. reported a net loss of $8.1 million for the three months ended June 30, 2026, compared to a net loss of $7.4 million for the same period in 2025. For the six months ended June 30, 2026, the company experienced a significantly larger net loss of $73.6 million, up from $15.6 million in the prior year. The increase in losses is attributed to a substantial fair value change in financial instruments, which resulted in a $44.2 million expense for the first half of 2026, compared to a $3.7 million income in the same period of 2025. License and collaboration revenue also decreased, totaling $0.8 million for the second quarter of 2026, down from $2.9 million in the prior year, primarily due to reduced research and development services under the Viatris License Agreement.

Operating expenses for the second quarter of 2026 rose to $17.2 million, compared to $11.8 million in the same quarter of 2025. This increase was driven by higher research and development costs, which reached $11.2 million, up from $6.0 million in the previous year. The rise in expenses reflects the company's ongoing commitment to advancing its gene therapy pipeline, particularly for inherited retinal diseases (IRDs). General and administrative expenses also saw a slight increase, totaling $6.0 million for the second quarter of 2026, compared to $5.8 million in the same quarter of 2025.

In terms of strategic developments, Opus Genetics has made significant progress in its clinical programs. The company is advancing multiple gene therapy candidates, including OPGx-LCA5 and OPGx-BEST1, which are currently in clinical trials. The FDA has granted various designations to OPGx-LCA5, including Rare Pediatric Disease and Regenerative Medicine Advanced Therapy designations, indicating the potential for expedited review processes. Additionally, the company successfully completed a Type B meeting with the FDA regarding its registration strategy for OPGx-LCA5, which is expected to enter a pivotal Phase 3 trial soon.

As of June 30, 2026, Opus Genetics reported cash and cash equivalents of $88.8 million, a significant increase from $45.1 million at the end of 2025. This increase is largely due to financing activities, including a $35 million tranche from a senior secured note purchase agreement and proceeds from a private placement of Series B preferred stock. The company believes its current cash reserves will be sufficient to fund operations for at least the next 12 months. However, it anticipates that ongoing clinical trials and development activities will continue to drive expenses, and it may need to raise additional funds in the future to support its growth and operational needs.